- Advertisement -spot_img
Sunday, September 25, 2022

J&J vaccine likely linked to two more serious health conditions, EU regulator finds

The European Union’s drug regulator recommends updating the label for Johnson & Johnson’s Covid-1 vaccine vaccine on October 1, which could warn of two more serious health conditions associated with the vaccine.

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has concluded that the use of the J&J vaccine may be associated with venous coagulation and an immune condition that causes the immune system to attack blood platelets.

“The PRAC has concluded that the Covid-1V vaccine has a potential link with Janssen in rare cases of venous thromboembolism (VTE),” the committee meeting highlighted.

Venus thromboembolism is a condition where blood clots in a deep vein, usually in one leg, arm or groin, and can go into the lungs, interfering with blood supply, with potentially fatal consequences, the committee said.

Janssen, a J&J company, did not respond to a request for comment.

Kovid-1 is a disease caused by the CCP (Chinese Communist Party) virus, commonly known as the novel coronavirus.

After reviewing the new evidence, the PRAC concludes that there is a “reasonable possibility” that the coagulation condition is associated with the vaccine using the J&J vaccine. The committee recommended listing venous thromboembolism as a rare side effect in product information for the J&J vaccine.

The committee also found that the use of J&J and AstraZeneca vaccines is associated with an immune condition that targets healthy platelets needed by the body’s immune system for normal blood clotting.

“Very low levels of blood platelets can be associated with bleeding and have serious health consequences,” the committee said.

PRAC recommends listing immune conditions for both the J&J and AstraZeneca vaccines as “adverse reactions with an unknown frequency.”

The regulator agreed to send direct warning statements to healthcare practitioners on both frostbite and disease resistance.

Communications for immune thrombocytopenia (ITP) have been reported to occur in the first four weeks after vaccination and are “included in severe cases, including very low platelet counts.”

“If a person has a history of ITP, healthcare professionals should consider the risk of developing low platelet levels before vaccinating. In people with a history of ITP, it is recommended to monitor platelet levels after vaccination with the Covid-1V vaccine Janssen. ”Says direct contact with doctors.

The message to doctors regarding venous thromboembolism (VTE) states that examples of this condition are rare, but the risk of this condition should be considered for those who have a risk factor for blood clots. The message further stated that patients with one of the two conditions should be tested for the other.

“This is important for the possible diagnosis of thrombosis, including thrombocytopenia syndrome (TTS), which requires special clinical management,” says Contact.

The US Food and Drug Administration (FDA) approved the J&J vaccine for emergency use on February 2, 2021. Less than two months later, on April 2, the FDA approved the amendment “to include very rare and serious types of information. Blood clots form in people who receive the vaccine. In that case, the condition of freezing was different from the flag marked by the European regulator on October 1.

The FDA did not respond to a request for comment.

Follow

Evan has been reporting on The Epoch Times since 2011.

.

This News Originally From – The Epoch Times

World Nation News Desk
World Nation News Deskhttps://worldnationnews.com/
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here